Dsp107 (Not yet branded)
Other Medications
Description
DSP107 is a novel therapeutic compound being developed for advanced colorectal cancer treatment, particularly in combination with the PD-L1 inhibitor atezolizumab. This agent has shown activity across multiple solid tumor types and is being evaluated as an alternative to established anti-angiogenic therapies like fruquintinib. DSP107 appears to target tumors regardless of specific biomarker status, including those with KRAS, BRAF, HER2, EGFR, NTRK, and RET mutations.
Mechanism of Action
DSP107's exact molecular mechanism has not been fully disclosed, but based on its clinical development pattern and combination with immunotherapy agents, it likely modulates immune response pathways or targets angiogenesis. The drug appears to work synergistically with PD-L1 inhibition to enhance anti-tumor immune responses in microsatellite stable colorectal cancers.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 Estado EMA | Experimental |
 Acceso España | med_spain_not_available |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.